Suven Pharmaceuticals’ arm gets EIR from USFDA for pre-approval inspection

04 Oct 2022 Evaluate

Suven Pharmaceuticals’ wholly owned subsidiary -- Casper Parma has received EIR from US Food and Drug Administration (USFDA) for its pre-approval inspection (PAI). The pre- approval inspection was conducted during July 25, 2022 through July 29, 2022. The inspection concluded with no observation (FDA-483) issued. Pre-Approval Inspections covering of three applications: NDA 016084, ANDA 217020 and ANDA 217030.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

Suven Pharma Share Price

1180.90 -37.40 (-3.07%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.